Indefinite Delivery Contract SPE2DU25D7070

The federal contract IDV award, valued at $9,999,999,999, was issued by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, which runs through December 2036, is an Indefinite Delivery Contract (IDC) that enables the DLA to procure a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This includes specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic domains. The contract was not set aside for any specific program and was awarded through full and open competition. Additionally, Amerisourcebergen holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs. These contracts allow the government to efficiently procure essential pharmaceutical and medical supplies to serve the healthcare needs of military personnel, veterans, and other federal beneficiaries.

The original solicitation, which is expected to be issued in March 2024, seeks to establish Pharmaceutical Prime Vendor Global Program Generation V contracts to provide worldwide pharmaceutical support to various DoD customers. The government intends to make multiple awards for separate regions, with at least three different contractors selected across the North/EUCOM, West/PACOM, South/SOUTHCOM, and Fleet line items. Both primary and backup suppliers will provide separate distribution fees for brand/generic and specialty pharmaceuticals to support normal and contingency operations globally. The estimated total value of the procurement is $30.3 billion, and the contract will have a 30-month base period with three 30-month option periods.